Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Endocrinology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Endocrinology Other
    Everolimus and Octreotide Combination Shows Promise for Neuroendocrine Tumours: Presented at ENETS - (DGDispatch)
    Serum Chromogranin A Marker Sensitivity Dependent on Primary Tumour Location: Presented at ENETS - (DGDispatch)
    Expression of Plasma Chromogranin A Can Predict Intestinal Carcinoid Tumour Burden: Presented at ENETS - (DGDispatch)
    Thyroid Hormone Analogue Shows Promise for Treating High Cholesterol - (DGNews)
    Liver Resection May Be Useful in Some Cases of Metastatic Adrenocortical Carcinoma: Presented at SSO - (DGDispatch)

    News archive

     Recent webcasts/CME - Endocrinology Other
    • Optimizing Insulin-Dependent Diabetes Management in Long-Term Care
    • Insulin-Dependent Diabetes in Long-Term Care: Scope of the Problem and Effective Management
    • Insulin-Dependent Diabetes in Long-Term Care: Practical Considerations
    • Anabolic Therapy for Osteoporosis
      PreAnesthetic Assessment of the Patient with von Hippel-Lindau Syndrome

      Webcasts/CME archive

       Recent cases - Endocrinology Other
        Solitary Adrenal Metastasis From Invasive Ductal Breast Cancer: An Uncommon Finding
        A Case of Pediatric Virilizing Adrenocortical Tumor Resulting in Hypothalamic-pituitary Activation and Central Precocious Puberty Following Surgical Removal
        Adrenal Failure Caused by a Retroperitoneal Malignant Mesothelioma
        Impetigo Herpetiformis During The Puerperium Triggered By Secondary Hypoparathyroidism: A Case Report
        Laparoscopic Resection Of A Large Adrenal Myelolipoma: A Case Report

        Cases archive
          




        my personal edition > endocrinology other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Pegvisomant Effective in Acromegaly Regardless of Response to Prior Therapy: Presented at ECE

        By Alison Palkhivala

        LYON, FRANCE -- April 29, 2003 -- Pegvisomant is an effective treatment for acromegaly, regardless of whether patients have been treated in the past or how they responded to previous therapy.

        Dr. Peter J. Trainer, from the department of endocrinology, Christie Hospital, Manchester, England, and colleagues investigated whether response to pegvisomant in patients with acromegaly can be predicted by previous response to other therapies.

        Results were presented in a poster here on April 29th at the 6th European Congress of Endocrinology.

        Pegvisomant is a pegylated analog of human growth hormone that acts as a competitive growth hormone receptor antagonist. The research was conducted in collaboration with Pharmacia Corporation, manufacturers of pegvisomant under the trade name Somavert®.

        One hundred and twelve patients with acromegaly had participated in a short- or long-term trial with pegvisomant. As part of a retrospective analysis of these patients, the investigators determined that, prior to participating in the trial, 22 patients had been drug naïve, 40 had been previously treated with medical therapy for acromegaly but were not on treatment immediately prior to receiving pegvisomant, 19 were octreotide responsive and 30 were octreotide resistant. Resistance to octreotide was defined as a failure of this agent to lower insulin like growth factor 1 (IGF-1) to an age-related reference range.

        Use of pegvisomant at a mean dose of 15.9 mg/day normalised IGF-1 for at least one visit in 91% of drug-naïve patients and 94% of previously treated patients. It also normalised IGF-1 for at least one visit in 89% of octreotide responsive patients and 97% of octreotide resistant patients. None of these values were significantly different from each other.

        Mean IGF-1 concentrations as well as sign/symptom scores of acromegaly were significantly reduced with pegvisomant therapy in all patient groups. Ring size was also reduced similarly in all four groups (P</=≤0.01).

        In their poster, the authors concluded that, "irrespective of previous therapy, pegvisomant is highly effective in treating patients with acromegaly."


        [Study title: Pegvisomant Is Effective For Acromegaly Irrespective Of Previous Medical Therapy. Abstract: P1139.]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2010 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send